CGL
LYEL icon

Clarius Group LLC’s Lyell Immunopharma LYEL Stock Holding History

Clarius Group LLC’s Portfolio LYEL Stock Details LYEL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$614K Hold
19,958
– – 0.04% 174
2025
Q3 		$324K Buy
19,958
+820
+4% +$9.37K 0.02% 286
2025
Q2 		$169K Sell
19,138
-820
-4% -$7.47K 0.01% 461
2025
Q1 		$215K Hold
19,958
– – 0.01% 446
2024
Q4 		$255K Hold
19,958
– – 0.02% 356
2024
Q3 		$551K Hold
19,958
– – 0.04% 204
2024
Q2 		$579K Hold
19,958
– – 0.04% 194
2024
Q1 		$890K Hold
19,958
– – 0.06% 135
2023
Q4 		$774K Hold
19,958
– – 0.06% 162
2023
Q3 		$587K Hold
19,958
– – 0.06% 194
2023
Q2 		$1.27M Buy
19,958
+19,138
+2,334% +$1.06M 0.1% 112
2023
Q1 		$38.7K Hold
820
– – ﹤0.01% 504
2022
Q4 		$57K Hold
820
– – 0.01% 504
2022
Q3 		$120K Hold
820
– – 0.01% 472
2022
Q2 		$107K Hold
820
– – 0.01% 456
2022
Q1 		$127K Hold
820
– – 0.01% 484
2021
Q4 		$127K Buy
+820
New +$183K 0.01% 484

Other funds holding LYEL

AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
GP
GSK plc London $599M AUM
MCL
MWG Caph Ltd Charlestown $72.4M AUM
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return
OPL
Orland Properties Ltd Road Town, Tortola, British Virgin Islands $267M AUM 5.05% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return
FCMV
Foresite Capital Management V Larkspur, California $271M AUM 309.87% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return

Clarius Group LLC's LYEL Position: Q4 2025 in Review

Clarius Group LLC held its Lyell Immunopharma (LYEL) position steady in Q4 2025 at 19,958 shares worth $614K. The position accounts for 0.04% of the portfolio, ranked #174.

Clarius Group LLC first reported a position in LYEL in Q4 2021 and has held it in 17 quarters since. The position peaked at $1.27M in Q2 2023. 68 funds tracked by Wall St. Rank hold LYEL as of Q4 2025.

  • Clarius Group LLC held 19,958 shares of Lyell Immunopharma worth $614K as of Q4 2025.
  • Clarius Group LLC left its Lyell Immunopharma share count unchanged in Q4 2025.
  • Lyell Immunopharma made up 0.04% of Clarius Group LLC's portfolio in Q4 2025, its #174 holding.
  • Clarius Group LLC first reported a position in Lyell Immunopharma in Q4 2021 and has held it in 17 quarters since.
  • Clarius Group LLC's Lyell Immunopharma position peaked at $1.27M in Q2 2023.
  • 68 funds tracked by Wall St. Rank held Lyell Immunopharma as of Q4 2025.

Based on Clarius Group LLC's 13F filing for Q4 2025, filed 14 Jan 2026.